Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14:00 | CERO THERAPEUTICS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
Mo | CERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors | 1 | RTTNews | ||
Mo | CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors | 55 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
Do | CERo Therapeutics gears up for clinical trial of cancer therapy | 1 | Investing.com | ||
Do | CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing | 49 | GlobeNewswire (Europe) | Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025 SOUTH SAN FRANSCISCO... ► Artikel lesen | |
19.03. | CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services | 72 | GlobeNewswire (Europe) | Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
13.03. | CERo Therapeutics präsentiert vielversprechende präklinische Studie zu Eierstockkrebs | 2 | Investing.com Deutsch | ||
CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
13.03. | CERo Therapeutics berichtet über positive präklinische Ergebnisse bei Krebsbehandlung | 1 | Investing.com Deutsch | ||
13.03. | CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting | 89 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
06.03. | CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays | 92 | GlobeNewswire (Europe) | Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:... ► Artikel lesen | |
05.03. | CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14 | 2 | GlobeNewswire (USA) | ||
06.02. | CERo Therapeutics strengthens cash reserves, advances clinical trials | 2 | Investing.com | ||
06.02. | CERo Therapeutics Holdings, Inc. Highlights Progress | 185 | GlobeNewswire (Europe) | Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings... ► Artikel lesen | |
06.02. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
06.02. | CERo Therapeutics to raise $5M via ATM offering | 2 | Seeking Alpha | ||
06.02. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
05.02. | CERO THERAPEUTICS HOLDINGS, INC. - S-1/A, General form for registration of securities | - | SEC Filings | ||
21.01. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
21.01. | CERO THERAPEUTICS HOLDINGS, INC. - S-1/A, General form for registration of securities | - | SEC Filings | ||
07.01. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
TEMPUS AI | 47,430 | -1,68 % | Decoding Tempus AI's Options Activity: What's the Big Picture? | ||
EVOTEC | 6,125 | +1,07 % | Deutz, Evotec, HelloFresh, Hensoldt, K+S, Verbio u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
BIONTECH | 85,05 | +3,15 % | BioNTech Aktie: Analysten setzen auf Onkologie-Wende | Nach dem Ende des COVID-Booms richtet sich der Blick bei BioNTech zunehmend auf die Onkologie-Pipeline - allen voran auf den Antikörper BNT327. Analysten erkennen in dem bispezifischen Kandidaten Potenzial... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 14,920 | -6,22 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
BIOAFFINITY TECHNOLOGIES | 0,777 | +182,36 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
BEAM THERAPEUTICS | 18,400 | -5,86 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,280 | -0,09 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
GRI BIO | 3,080 | -3,75 % | GRI Bio, Inc.: GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan | Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA,... ► Artikel lesen | |
GUBRA | 60,60 | +8,60 % | Gubra-Aktie +15%: Zeit fürs Comeback! | Die Gubra-Aktie ist in den letzten vier Wochen unter massiven Verkaufsdruck geraten und hat über ein Drittel ihres Wertes eingebüßt. Doch am Dienstagmorgen sendet das Papier des dänischen Biopharmaunternehmens... ► Artikel lesen | |
CORCEPT THERAPEUTICS | 86,46 | -18,16 % | Corcept Therapeutics Incorporated: Primärer Endpunkt der zulassungsrelevanten Phase-3-ROSELLA-Studie von Corcept zu Relacorilant bei Patientinnen mit platinresistentem Eierstockkrebs erreicht | Relacorilant plus nab-Paclitaxel verbessert das progressionsfreie und das Gesamtüberleben ohne verstärkte Nebenwirkungen Ergebnisse unterstützen Marktzulassungsanträge in den USA (NDA)... ► Artikel lesen | |
MODERNA | 25,340 | -3,32 % | Moderna-Aktie leicht im Minus (29,9070 €) | Der Anteilsschein von Moderna notiert heute ein wenig leichter. Der jüngste Kurs betrug 32,24 US-Dollar. Für der Anteilsschein von Moderna steht gegenwärtig ein Abschlag von 4,13 Prozent zu Buche. Die... ► Artikel lesen | |
IMMUNOVANT | 16,510 | -3,34 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 42,940 | -2,74 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen |